))
Dermatology Edition: Top Headlines for Week of October 16, 2023
Manage episode 407442253 series 3560281
Kandungan disediakan oleh Healio. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Healio atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more. Read the full coverage here:
FDA issues complete response letter for relabotulinumtoxinA for frown lines, crow’s feet
Mucocutaneous manifestations may signal COVID-induced inflammatory disease in children
FDA approves Zoryve for pediatric psoriasis
Colloidal oatmeal, prescription cream comparable in Black children with atopic dermatitis
FDA issues complete response letter for lebrikizumab for eczema treatment
References:
Imam B. Mucocutaneous clinical manifestation of multi-system inflammatory syndrome in children (MIS-C). Presented at: Skin of Color Update; Oct. 6-8, 2023; New York.
Lisante TA, et al. J Dermatolog Treat. 2023;doi:10.1080/09546634.2023.2241587.
120 episod
Kongsi
